APNewsBreak: Feds balk at paper health application
FORT LAUDERDALE, Fla. (AP) Federal health officials, after encouraging alternate sign-up methods amid the fumbled rollout of their online insurance website, began quietly urging counselors around the country this week to stop using paper applications to enroll people in health insurance because of concerns those applications would not be processed in time.
Sat, 07 Dec 2013 12:00:13 -0500
Gene therapy scores big wins against blood cancers
In one of the biggest advances against leukemia and other blood cancers in many years, doctors are reporting unprecedented success by using gene therapy to transform patients' blood cells into soldiers that seek and destroy cancer.
Sat, 07 Dec 2013 20:10:59 -0500
Hong Kong reports 2nd H7N9 bird flu case
HONG KONG (AP) Hong Kong reported its second human case of H7N9 bird flu just days after the first, raising fears that the virus is spreading beyond mainland China.
Fri, 06 Dec 2013 21:25:09 -0500
Stop, Listen, Pray, Meditate
I woke up yesterday morning and for some reason I felt an urge to sit on the side of my bed and immediately began to meditate and pray. I usually go into the living room, relax with a cup of my homemade tea or some coffee, and ease into my day with my meditation and prayer practice. But yesterday I felt I had to begin immediately after waking up. I sat and at first I just listened. I focused on my breath and listened to the inner whisper that told me today someone unexpected would need me to be there
Sun, 08 Dec 2013 20:34:12 -0500
Singer Susan Boyle reveals she has Asperger's syndrome: paper
(Reuters) - Scottish singer Susan Boyle says she has a form of autism known as Asperger's syndrome, a diagnosis she says came as a relief after years of believing she had brain damage. Boyle, 52, told the Observer newspaper in an interview published Saturday she had sought help from a Scottish specialist a year ago believing her childhood diagnosis of brain damage was incorrect. "I was told I had brain damage.
Sun, 08 Dec 2013 12:51:54 -0500
AbbVie leukemia drug impresses in early-stage trial
An experimental AbbVie Inc drug for leukemia controlled or eliminated signs of the disease in more than 80 percent of patients who had failed to benefit from previous treatments, an unprecedented finding that could spur use of the medicine for other cancers, researchers said. The AbbVie drug, ABT-199, works by blocking a protein called BCL-2 that allows cancer cells to overcome a natural mechanism called programmed cell death, in which the body kills off defective or cancerous cells. The favorable data was seen in a phase I, or early-stage, trial involving 67 patients with chronic lymphocytic leukemia who had not been helped by chemotherapy or relapsed from such treatment. "To achieve that magnitude of complete remission is extraordinarily promising and unprecedented in this particular type of leukemia, among patients with otherwise resistant disease," Dr. John Seymour, a researcher with the Peter MacCallum Cancer Centre in Melbourne, Australia, said in a telephone interview.
Sun, 08 Dec 2013 10:30:54 -0500
J&J, Pharmacyclics leukemia drug effective long term: study
A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting. The oral drug, ibrutinib, last month won U.S. approval to treat a rare and aggressive form of non-Hodgkin lymphoma known as mantle cell lymphoma. It is awaiting a Food and Drug Administration decision on treating chronic lymphocytic leukemia (CLL), a slowly progressing form of blood cancer that primarily affects people aged 65 and older. Some industry analysts had expected the CLL approval to come at the same time as the lymphoma decision.
Sun, 08 Dec 2013 10:09:02 -0500
Teva bets on new therapeutic uses of known molecules
By Tova Cohen TEL AVIV (Reuters) - Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018. This figure could jump to $3 billion in 2020, Elisabeth Kogan, Teva's senior vice president of generic research and development, told reporters on Sunday. The NTE program, launched a year ago, is a major element in Teva's strategy for growth and the company has 15 such products in its pipeline. One such product, called Adasuve, which it licensed from Alexza Pharmaceuticals, has been approved and is expected to be launched in the United States in about a month, Teva officials said.
Sun, 08 Dec 2013 10:04:44 -0500
China bans shark fin dinners, suites for officials in latest crackdown
Chinese authorities have banned shark fin and bird's nest soup from official receptions and told lower level officials they cannot stay in suites on business trips in the latest step in a crackdown on extravagance and waste. The official Xinhua news agency said on Sunday that cigarettes and expensive alcoholic drinks were also banned from official receptions, citing a document issued by the Communist Party's Central Committee and the State Council. "Shark fins, bird nests and products of rare wild animals are popular materials in luxury dinners in China," Xinhua cited the document as saying. "Officials on business tours should arrange their own meals according to relevant expenditure standards." Chinese President Xi Jinping has sought to address growing public anger at the illegal or unethical behavior of party officials, especially those with flamboyant lifestyles, often seen as a sign they are corrupt.
Sun, 08 Dec 2013 09:55:53 -0500
Copyright (c) 2013 Yahoo! Inc. All rights reserved